This study, although small and uncontrolled, suggests that acceptable rates of remission in primary membranous nephropathy may be achieved using lower cumulative doses of cyclophosphamide compared with usually used current regimens.
SUMMARY AT A GLANCE
This study, although small and uncontrolled, suggests that acceptable rates of remission in primary membranous nephropathy may be achieved using lower cumulative doses of cyclophosphamide compared with usually used current regimens.
ABSTRACT:
Aim: Primary membranous nephropathy is associated with progression to end stage renal diseasein some patients. Standard therapy with cyclical cyclophosphamide and corticosteroids can be associated with significant adverse effects. We aimed to assess immunological and clinical response with intravenous pulse cyclophosphamide and oral steroids in patients with severe nephrotic syndrome -in a prospective observational cohort study.
Methods: A total of 17 consecutive patients (nine new-incident and eight relapses) with severe nephrotic syndrome received monthly intravenous pulse cyclophosphamide and oral steroids after failure to achieve remission with supportive therapy. Immunosuppressive therapy was discontinued at 6 months or earlier if proteinuria regressed to <100 mg/mmol and patients were followed for 12 months. Achievement of partial remission was primary outcome; changes in clinical parameters and anti-PLA 2 R were secondary outcomes.
Results: Dose of cyclophosphamide received was 5.4 g in New-incident patients and 4.2 g in patients with relapses. All 17 patients achieved partial remission within 6 months: proteinuria improved from 656 to 102 mg/mmol at 6 months and 55 mg/mmol at 12 months (P < 0.001); eGFR improved from 31 to 48 mL/min per 1.73 m 2 at 6 months and 45 mL/min per 1.73 m 2 at 12 months (P < 0.05). Anti-PLA 2 R levels reduced from 244 to 10 U/L at 6 months and 10 U/L at 12 months (P < 0.001). Two out of nine patients in the New-incident group developed subsequent relapse. Cumulative doses of cyclophosphamide and steroids that patients received was about half of the standard regime.
Conclusion: Pulse cyclophosphamide with oral steroids induced immunological and clinical partial remission at significantly reduced doses in primary membranous nephropathy.
Primary membranous nephropathy (PMN) is a common cause of nephrotic syndrome in adults and progresses to end stage renal disease (ESRD) in a proportion of patients. 1 Evidence and current guidelines recommend therapy with cyclophosphamide-based regimes in patients at risk of progression or in those with severe and persistent nephrotic syndrome. [2] [3] [4] Achieving partial remission provides good prognosis in the long term 5, 6 and is considered a useful end point during therapy. Therapy with cyclophosphamide is associated with potential short term and longer term toxicity which is more widely reported in literature from lymphoma and antineutrophil cytoplasmic antibody associated vasculitis. [7] [8] [9] This may lead to reluctance on part of physicians and patients to use such therapy in some individuals 5, 10 which could lead to under-treatment of the disease process, increasing the risk of progression to ESRD and its consequences. Search for alternative therapies that can reduce drug toxicity profile without reducing efficacy continues.
outcomes. 5 Management of relapses is less well studied, with previous reports from 1990s showing good response with therapy with various agents including steroids alone, or with combination of immunosuppressants including cytotoxic agents. 14, 15 Repeated courses of therapy for relapses potentially increase the cumulative dose of alkylating agents with its attended risks.
Since the breakthrough discovery of PLA 2 R and anti-PLA 2-R 16 and their specificity in PMN, there has been accumulating evidence into immunological aspects and effects of these antibodies on outcomes. Retrospective and prospective data 17, 18 showed that anti-PLA 2 R response precedes response in proteinuria. It is speculated that targeting therapy to immunological response may achieve better outcomes by reducing prolonged exposure to immunosuppressive agents. 19 However, immunological response with cyclophosphamide-based therapy is not well studied. Experience and trials in ANCA associated vasculitis over the past two decades showed that intravenous pulse therapy with cyclophosphamide could reduce the cumulative dose thereby contributing to reduction in adverse effect profile; this was seen without reducing clinical effectiveness in achieving disease remission. 20 A similar approach is used in some centres, including ours, to treat PMN to reduce the cumulative dose thereby limiting potential drug toxicity. 5, 10 Use of Intravenous pulse cyclophosphamide with steroids in idiopathic membranous nephropathy was reported with variable success in previous studies. [21] [22] [23] The aim of this study is to evaluate and report the clinical and immunological course of the disease in patients receiving pulse cyclophosphamide-based therapy, for New-incident episodes and relapses of nephrotic syndrome from PMN.
METHODS
This is a single centre study of adult patients aged ≥18 years with PMN who were referred with nephrotic syndrome. All New-incident patients had diagnosis of PMN based on clinical and histological criteria; and did not receive any previous immunosuppressive therapy. Patients with diabetes mellitus and previous history of malignancy were excluded. In those with relapses, immunosuppressive therapy was used only for the initial episode following their New-incident diagnosis. Biopsy was not undertaken routinely in patients with relapses (but patients had previously confirmed biopsy proven PMN during their first presentation). Secondary causes were excluded as per standard policy -screening for occult malignancy was undertaken if patients had no clinical features of such a cause, were aged >60 years and if serum was negative for anti-PLA 2 R. Written informed consent was obtained and all patients were recruited into the AutoMN study (Medical Research Council, UK, MR/J010847/1), exploring the immunological mechanisms and genetic control involved in PMN.
Supportive therapy included (unless contraindicated) -standard therapy of BP, diuretics as necessary, Renin-Angiotensin inhibitors and statins for up to 6 months before therapy, anticoagulation with warfarin or low molecular weight heparin for the period of severe nephrotic syndrome (if urine protein-creatinine ratio (uPCR) > 300 mg/mmol and serum albumin <20 g/L).
Immunosuppressive Therapy: 1 Intravenous pulse cyclophosphamide at a dose of 600 mg/m 2 every 4 weeks -for up to 6 months; in conjunction with 2 Oral steroids: Prednisolone at a dose of 0.75 mg/kg daily (up to 60 mg/day) -with gradual tapering to 0.5 mg/kg per day by 3 months and 0.1 mg/kg per day by 6 months. Cyclophosphamide pulses were discontinued either after six doses or earlier if proteinuria regressed to <100 mg/mmol during therapy.
Azathioprine: Incremental increase of Azathioprine was used after induction of partial remission, (upto 50-100 mg/day), if patients had persistent proteinuria (>100 mg/ mmol) after 6 months of induction therapy and either: (i) poor renal function (MDRD eGFR <30 mL/min); or (ii) persistent elevation of Anti-PLA 2 R antibodies. Azathioprine was discontinued after a total duration of 12 months.
Prophylaxis with co-trimoxazole and fluconazole was undertaken in all patients for the duration of cyclophosphamide therapy and gastric prophylaxis was undertaken with proton pump inhibitors. Monitoring for toxicity and effectiveness was undertaken 2-weekly for 6 months after initiation of cyclophosphamide therapy and 3-monthly thereafter. Clinical and serological data were collected prospectively as patients were followed up for at least 12 months.
End points
The primary end point was partial remission of proteinuria throughout the study in both groups. Secondary end points were eGFR at 1 year, anti-PLA 2 R response throughout the observation period and complete remission.
Clinical indicators and definitions

Partial remission
At least 50% reduction in proteinuria from baseline and uPCR <300 mg/mmol with stable renal function (<15% drop in eGFR). Decline in proteinuria was confirmed on repeat measurements.
CKD-5
A 4-variable MDRD eGFR < 15mL/min per 1.73 m 224 or initiation of renal replacement therapy.
Anti-PLA 2 R
Serum was assayed for anti-PLA 2 R by ELISA at New-incident presentation and at relapse, as per previous descriptions. 25 Serial assays were undertaken monthly during the course of therapy and at three monthly intervals following induction therapy.
Continuous data was summarized as median (with range or interquartile range) and groups compared using MannWhitney test. Categorical data was expressed in percentage and compared using Fisher's exact tests. Two-tailed P-values <0.05 were considered statistically significant. 
RESULTS
From January 2013 until June 2015 -40 patients were diagnosed with biopsy proven New-incident nephrotic syndrome from PMN. A total of 13 patients with previously diagnosed PMN who were under regular follow up of the unit developed relapse of NS during the same time ( Fig. 1) . A total of 17 patients received immunosuppressive therapy with combined pulse intravenous cyclophosphamide and daily oral prednisolone -nine patients with New-incident diagnosis of PMN and eight patients with relapses of nephrotic syndrome. Tables 1-3 include features at baseline and during follow up respectively for all these patients divided into two groupsNew-incident patients and patients presenting with relapses. Seven out of eight patients with relapses were men. All patients had severe nephrotic syndrome at presentation that showed no sign of improvement during non-immunosuppressive antiproteinuric therapy alone. Patients received such therapy for a median of 6 months in New-incident group and 4 months in relapse group before initiation of immunosuppressive therapy. Most of the patients had abnormal renal function at presentation which, during follow up with lone supportive therapy reduced in both subsets of patients (51 mL/min at presentation to 35 mL/min at initiation of therapy in New-incident patients, 46 mL/min at presentation to 30 mL/min at initiation of therapy in relapses). The median duration of follow up was 32 months in New-incident patients and 19 months in relapses of nephrotic syndrome. Doses of cyclophosphamide: In New-incident cohort -median dose of cyclophosphamide received was 5.4 g over four Pulse Cyclophosphamide in Primary MN to six monthly pulses, and in patients with relapses -4.2 g over three to six monthly pulses (Table 4 ). In New-incident cohort, one patient did not receive renin-angiotensin inhibitors because of decline in renal function ascribed to the drug by physician (major renal arterial stenosis was excluded). All patients received loop diuretics to help manage oedema and statins for hypercholesterolemia. Five out of nine patients in New-incident cohort received prophylactic anticoagulation. One patient with relapse had serum albumin <20 at presentation and so received prophylactic anticoagulation.
Two patients in the New-incident group (one with eGFR < 30 mL/min + moderate proteinuria and one with elevated anti-PLA 2 R at end of 6-month induction therapy + moderate proteinuria) received Azathioprine for a total duration of 12 months. One patient in relapse group had eGFR < 30 mL/min + moderate proteinuria and received Azathioprine for a duration of 12 months.
End points
All nine patients in New-incident cohort and eight patients in relapse cohort achieved partial remission by the end of induction therapy (Fig. 2) . The median duration of time to partial remission from initiation of immunosuppression was 2.1 and 2.3 months, respectively. Complete remission was seen in four (44%) patients in New-incident cohort and four patients (50%) in relapse cohort during follow up. In the whole cohort, median proteinuria improved from 656 mg/mmol at initiation of therapy to 102 mg/mmol at 6 months and 55 mg/mmol at 12 months. Median eGFR improved from 31 mL/min per 1.73 m 2 at initiation of therapy to 48 mL/min per 1.73 m 2 at 6 months and 45 mL/min per 1.73 m 2 at 12 months.
There was no significant difference in proteinuria between time at presentation to the time at initiation of therapy (750 vs 656 mg/mmol, P = 0.59); no significant difference in serum albumin during this time (23 vs 20 g/dL, P = 0.46); but there was decline in renal function during this time of observation although not statistically significant (51 vs 31 mL/min per 1.73 m 2 , P = 0.07). Temporal response with clinical parameters and immunological response is shown in Fig. 3 according to the subgroups (New-incident and relapsed patients). There was significant improvement in these parameters by month six and month 12 and up until last follow up, compared to time at initiation of therapy (Table 3) .
Immunological response (Anti-PLA 2 R antibodies)
Eight out of nine patients in New-incident cohort were seropositive for anti-PLA 2 R at presentation and through the course of active disease, and all eight patients in relapse cohort were seropositive. However, there was a distinct difference in anti-PLA 2-Rab profile in the two groups. Quantitative anti-PLA 2 R levels at presentation were significantly higher in New-incident group in comparison with patients with relapses (median of 2772 vs 60 U/mL, P < 0.05). There was significant decline in anti-PLA 2-R levels following immunosuppressive therapy in the eight patients in New-incident group -726 to 24 U/mL (P < 0.001). In these eight New-incident patients with anti-PLA 2 R positivity, anti-PLA 2 R IgG4 subclass constituted 72% of total anti-PLA 2 R IgG (47-86%).
Adverse events
One patient had chest infection that improved with antibiotics (no hospital admission). One patient had CMV syndrome and viremia that improved with oral Valganciclovir (no hospital admission). One patient needed hospital admission for severe fluid retention, 1 month after initiation of immunosuppressive therapy that was managed with intravenous diuretics and albumin infusion. One patient died 7 months after completing immunosuppressive therapy, because of a spontaneous intracerebral stroke. He remained in partial remission at the time of this event. Five out of 17 (29%) patients developed diabetes mellitus during therapy and needed hypoglycemic agents. Two of these patients recovered subsequently following steroid withdrawal needing only dietary management of diabetes mellitus during follow up.
DISCUSSION
There has been increasing interest in the pathogenesis and management strategies in PMN. This has been spurred by the discovery of PLA 2 R and anti-PLA 2 R in patients with PMN. It is well recognized that declining renal function in the context of persistent or severe nephrotic syndrome in PMN portends poor prognosis and progression to renal failure. 26, 27 Our data suggests that pulse cyclophosphamide-based therapy in patients with severe nephrotic syndrome reverses progression of disease and achieves partial remission with improvement of renal function. Similar clinical response was seen in both New-incident nephrotic syndrome as well as relapses of severe nephrotic state in patients with previous PMN. This study shows further insight into the immunological window during therapy for severe disease. Understanding the role of anti-PLA 2 R in pathogenesis as well response to therapy could hold the key in stratifying patients and could be incorporated into future trials. Knowledge of such response in prospective studies will help in designing future trials. The regime with alternating monthly cyclophosphamide and high dose steroids, 4 Ponticelli regime, is the current recommended therapy for use in regular clinical practice. Efficacy of this regime was widely demonstrated and is shown to be the commonly used approach in a recent survey of renal centres in UK. 10 Ponticelli et al. 4 found that 40 of 43 patients with New-incident NS who received alternating monthly cyclophosphamide and high dose methylprednisolone (followed by daily oral steroids; and followed up for at least 1 year) achieved remission. In the randomized controlled trial reported by Jha et al. 3 34 out of 47 patients (72%) achieved remission during follow up. Although not seen significantly in these two studies, toxicity of these therapeutic agents at a high dose could limit its wider use despite the potential persistence of disease activity in PMN. In addition, it is unknown if patients achieve partial remission during the period of intensive therapy and if so could be spared of exposure to full doses of immunosuppression. Although CNIs have been shown to be effective in inducing remission, their use is limited in patients with declining renal function. 28 Therefore, further studies are underway to look for alternative therapies and approaches; and if found effective could help in improving outcomes whilst reducing toxicity. 29 The pulse intravenous therapy allows for approximately 50% reduction of cumulative cyclophosphamide and steroid dose over a 6-month period that patients would have received with the conventional 6-month regime. This is similar to the findings of CYCLOPS study in ANCA-associated vasculitis. 20 Efficacy of this pulse regime appears similar in both Newincident and relapsed patients with 100% achievement of partial remission. All patients in both the groups achieved partial remission 6 months from initiation of therapy.
Two out of the nine patients in New-incident group developed relapse (nine and 24 months after initial therapy) of nephrotic syndrome. We could not comment if their risk of relapse would have been different if they received conventional 6-month regime. However, relapse of nephrotic syndrome was noted to be high in previous reports using a selective approach for identifying patients who needed therapy. 30 In one of the two patients with subsequent relapse anti-PLA 2 R was undetectable in serum for 2 months before therapy was stopped; whilst in the other patient anti-PLA 2 R was still detectable above the normal range (at a lower level -54 U/mL) at 6 months when therapy was stopped. This patient particularly had an early relapse 3 months after stopping therapy. This patient's ) and anti-PLA 2 R antibodies (U/mL) with time (in months after starting immunosuppression) according to groups -New-incident and relapses of nephrotic syndrome (median with inter-quartile ranges).
relapse responded after five additional months of therapy. This raises the question if therapy should take serological status into account along with clinical status. Bech et al. showed that elevated anti-PLA 2 R levels predict rate of subsequent relapse. 31 Larger scale studies are warranted to explore this effect.
In a recent study, we reported longer term effects of relapse on patient outcomes. 5 Therapy of relapses has not been systemically studied so far. Our study shows good response and achievement of partial remission following therapy of relapses with this pulse regime. Moreover, in this study, we find that some patients with relapsed nephrotic syndrome achieved significant improvement in proteinuria by 3 months and therefore did not need full 6 months of therapy. This approach allowed for individualisation of therapy and merits further evaluation. Similar to cumulative dose of cyclophosphamide, the dose of prednisolone was approximately 50% less than the conventional 6-month alternating regime. Contrary to our experience, previous studies have not shown such a high incidence of diabetes mellitus, and it may be related to patient factors or to increased vigilance in our study. Other adverse effects, in terms of infection, included chest infection and CMV viremia which were managed with interim measures although interruption of further dosing of cyclophosphamide was necessary.
Therapy with cyclophosphamide has bearing on subsequent morbidity including bladder related toxicity (including transitional cell carcinoma), myeloid dysplasia and non-melanoma skin cancer. 32 This is in addition to increased risk of infections in the short term and bone health and fertility in longer term. 9 In PMN, the study by van den Brand et al. showed an increase in incidence of malignancy in cyclophosphamide-treated patients by 3-fold (annual cancer risk from 0.3% to 1.0% in a 55-year old patient).
33 Dose-response relationship between cyclophosphamide therapy and malignancy risk was reported in some studies 8 although not in the van den Brand study. This variation may have been contributed by numbers in each group in reported studies. It is suggested that in ANCA associated vasculitis, less extensive use of immunosuppressants in current treatment protocols might result in a lower cancer risk compared with historical studies. 34 We speculate that similar approach in PMN has potential to reduce the lifetime cumulative dose and toxicity of cyclophosphamide exposure. This study shows other findings that may be relevant in future trials and clinical practice. anti-PLA 2 R levels in serum were significantly higher in New-incident patients compared with relapsed patients. This could be a consequence of the following: (i) earlier diagnosis in relapse; (ii) different biological responses in relapse such as antibodies to different epitopes 35 ; (iii) reduced reservoir of actively secreting plasma cells post immunosuppression; or (iv) previous immunosuppression in patients with relapses. Six out of eight patients with relapses received immunosuppression during the first nephrotic presentation from PMN, and there was a median interval of 65 months between the first presentation with nephrotic syndrome and their relapse episode (range of 13-210 months). Also this data suggests that utility of monitoring of anti-PLA 2 R and therapy directed at serology may be different in New-incident and relapsed patients. There is significant improvement in quantitative serum anti-PLA 2 R levels in New-incident patients -reduction by approximately 75% at 1 month after initiation of therapy, whilst proteinuria is reduced by about 50% by month two in all nine patients. This is in comparison with clearance after 9 months with Rituximab (in 18 out of 25 patients who cleared to undetectable level). 17 Also in the same study, only about 50% of patients achieved clinical remission at 12 months.
In our study, all eight patients who had high anti-PLA 2 R with New-incident nephrotic syndrome cleared the antibodies (to undetectable level) before month four (at which point median uPCR was still 189 mg/mmol). This clinical-immunological dissociation was reported in previously reported retrospective and prospective 17, 18 studies and raises the important question of appropriate therapy (withholding vs continuation of further immunosuppressive therapy) that warrants further study. This study makes a case for individualization of therapy based on close immunological and clinical monitoring.
Limitations
Our study has several limitations. The study is relatively small and is from an unselected population from a single centre, although describing all patients who received the regime for persistent active disease in PMN. There is no control group and improvements seen could be spurious or attributed to 'regression to the mean' phenomenon. However, multiple measurements in the group over a period of over 12 months consistently showing trends towards improvement in disease activity makes this less likely. We could not undertake multivariate analyses for outcomes of interest given small number of patients in the study. Also because of lack of control group, comparisons are drawn from previously published studies. Duration of follow up in the 'New-incident' group is more than the relapse group, but there was no plausible reason that could be noted. Despite the limitations, to our knowledge this is the only study showing comparable clinical and immunological outcomes with reduced doses of cyclophosphamide and steroids. Also, it provides prospective view into immunological status much more closely than previously reported. Patients were monitored as part of visits to hospital fortnightly during the induction therapy. This may have had an impact in rates of adverse events such as infections. Further evidence of such regime in a controlled and larger study would be necessary to influence patient outcomes in the wider context.
CONCLUSIONS
This prospective study in PMN demonstrates the efficacy of intravenous pulse cyclophosphamide with daily oral steroids with significant improvement in clinical and immunological status in both New-incident and relapsed patients. Further studies are needed to explore individualization of therapy to improve efficacy and adverse effect profile for patients with PMN.
